Chronic Lymphocytic Leukemia | Specialty

Expert Shares Insights on CLL Treatment Paradigm

July 20th 2018

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.

Regimen Shows Potential for Reducing TLS Risk in CLL

July 17th 2018

Kerry Rogers, MD, discusses the feasibility of a new treatment for tumor lysis syndrome and what research still needs to be done with these agents in chronic lymphocytic leukemia.

Despite New Treatments in CLL, Comparative Data and Guidance Slow to Emerge

July 15th 2018

With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.

Dr. Barrientos on the Challenges in CLL

July 14th 2018

Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.

Dr. Talley on Clinical Trials for Patients With Chronic Leukemias

July 13th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.

Dr. Talley on the CAPTIVATE Trial in CLL

July 10th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses the CAPTIVATE trial in patients with chronic lymphocytic leukemia (CLL).

CLL: The Rapidly Evolving Treatment Landscape

June 28th 2018

CAPTIVATE and iNNOVATE Clinical Trial Results for CLL

June 28th 2018

Addressing the Unmet Needs for the Treatment of CLL

June 28th 2018

Dr. Mato Discusses a Phase II Trial of Umbralisib in CLL

June 25th 2018

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses a phase II trial of umbralisib in chronic lymphocytic leukemia.

Dr. Davids Discusses Duvelisib in Relapsed/Refractory CLL

June 20th 2018

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib in relapsed/refractory chronic lymphocytic leukemia.

Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma

June 18th 2018

Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.

Dr. Mato Discusses the Safety and Efficacy of Umbralisib in CLL

June 17th 2018

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia.

Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL

June 17th 2018

The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.

Dr. Davids Discusses Duvelisib Plus FCR in Young Patients With CLL

June 16th 2018

Matthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.

Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option

June 15th 2018

The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

FDA Grants Venetoclax Full Approval for CLL, Regardless of 17p Deletion

June 8th 2018

The FDA has granted a regular approval to venetoclax for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, following at least 1 prior therapy. The BCL-2 inhibitor is now also approved for use in combination with rituximab in the same patient population.

Frontline Ibrutinib/Venetoclax Combo Shows High MRD-Negative Responses for CLL

June 4th 2018

The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.

Frontline Ibrutinib Plus Obinutuzumab Improves PFS in Phase III CLL Trial

May 24th 2018

Frontline treatment with the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) improved progression-free survival compared with chlorambucil plus obinutuzumab in patients with CLL or SLL.

Expert Assesses Available Treatments in CLL

May 18th 2018

Ryan W. Jacobs, MD, discusses the use of small molecule inhibitors in the treatment of patients with chronic lymphocytic leukemia.